SCYNEXIS, Inc. logo

SCYNEXIS, Inc.

NASDAQ:SCYX

Overview | Financials
Company Name SCYNEXIS, Inc.
Symbol SCYX
Currency USD
Price 1.27
Market Cap 48,077,755
Dividend Yield 0%
52-week-range 1.265 - 3.66
Industry Drug Manufacturers—Specialty & Generic
Sector Healthcare
CEO Mr. David Gonzalez Angulo M.D.
Website https://www.scynexis.com

An error occurred while fetching data.

About SCYNEXIS, Inc.

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal

Related Stocks

Bolt Biotherapeutics, Inc. logo

Bolt Biotherapeutics, Inc.

BOLT

0.648 USD

Bionomics Limited logo

Bionomics Limited

BNOX

0.595 USD

Qilian International Holding Group Limited logo

Qilian International Holding Group Limited

QLI

5.41 USD

Oncolytics Biotech Inc. logo

Oncolytics Biotech Inc.

ONCY

0.958 USD

Rain Therapeutics Inc. logo

Rain Therapeutics Inc.

RAIN

1.21 USD

Novo Integrated Sciences, Inc. logo

Novo Integrated Sciences, Inc.

NVOS

0.285 USD

Financials

Numbers are in millions USD

Numbers are in millions USD